Cambridge Cognition announced that it has secured a significant contract for a sizeable later stage clinical trial, following a competitive tender. The contract combines the Company's proprietary CANTAB®? touch-screen cognitive assessments with verbal assessments from its recent Winterlight Labs acquisition, for the first time.

Additionally, the Company will supply its electronic Clinical Outcome Assessments ("eCOA") and provide full training for clinicians, together with quality control services. This initial contract is valued at approximately PS1 million and revenue is expected to be recognised over a two-year period, starting in 2023. There is potential for a further contract with the same customer, of slightly higher value, in 2024 once the initial results have been analysed from this trial.